Affymetrix and DNA Link Sign Partnership for Forensic Test Development for Human Identification

  Affymetrix and DNA Link Sign Partnership for Forensic Test Development for
  Human Identification

Business Wire

SANTA CLARA, Calif. -- February 7, 2013

Affymetrix, Inc. (NASDAQ: AFFX) and DNA Link, Inc., a Korean genomics-based
biotechnology company, today announced that they have signed a Powered by
Affymetrix^TM (PbA) Program agreement in which DNA Link, Inc. obtains a
worldwide license to develop and commercialize a forensic test for
comprehensive human identification and other diagnostic tests using
Affymetrix’ microarray technology and the Korea FDA (KFDA) cleared GeneChip^®
System 3000Dx v.2.

AccuID^®Chip is a novel SNP marker based array for personal identification
which can be applied to a variety of forensic samples, including degraded DNA
samples. This array utilizes DNA Link’s unique approach of combining
Affymetrix’ target resequencing array technology and multiplexing PCR
technology to genotype hundreds of SNP markers in a single experiment to
obtain high quality data and a wide variety of information – all with high
throughput and cost efficiency.

Dr. Jong-Eun Lee, CEO of DNA Link, said, “The advantage of using SNP markers
is that they possess lower mutation rate than STR markers, thus are more
stable in terms of inheritance which could aid parentage testing, kinship
analysis, ethnicity, or predicting phenotypic characteristics. This novel
forensic test, AccuID^®Chip, can be used complementarily with existing STR
tests and to build a more comprehensive forensic database. We are pleased to
join the ranks of other PbA Program partners, such as Roche Diagnostics and
Pathwork Diagnostics in adopting the Affymetrix technology.”

“We are very pleased to have DNA Link join our Powered by Affymetrix program
in which we help partners to develop novel molecular diagnostic tests for
personalized healthcare. DNA Link being our first partner in Korea will also
provide our other PbA partners access to the Korean personalized genomics
market,” said Dara Wright, Vice President, Clinical Applications Marketing at
Affymetrix.

PLEASE NOTE:

AccuID^®Chip is not available for in vitro diagnostic use in the United
States.

Affymetrix^®, the Affymetrix logo, Powered by Affymetrix™, GeneChip^® and all
other trademarks are the property of Affymetrix, Inc. AccuID^®Chip is
trademark of DNA Link and all other trademarks are the property of their
respective owners.

SOURCE: Affymetrix, Inc.

About DNA Link, Inc.

DNA Link, Inc. (listed in KOSDAQ market), based in Korea, is a leading company
in genomics, personalized medicine, molecular diagnostics, and forensics. As a
genomics-based biotechnology company, DNA Link, Inc. has a complete genotyping
solution and resources for large-scale clinical research projects. DNA Link
put DNAGPS (Genomics Personalized Service), consumer genotyping service on the
Korean market in 2010 and plans to enter the China market in collaboration
with SK Chemicals. For further details about DNA Link, Inc., please visit
www.dnalink.com.

About Affymetrix

Affymetrix technologies are used by the world's top pharmaceutical,
diagnostic, and biotechnology companies as well as leading academic,
government, and nonprofit research institutes. More than 48,000 peer-reviewed
papers have been published citing the technologies. Affymetrix is
headquartered in Santa Clara, Calif., and has manufacturing facilities in
Santa Clara, San Diego, Cleveland, Ohio, Singapore, and Austria. The company
has about 1,100 employees worldwide and maintains sales and distribution
operations across Europe, Asia, and Latin America. For more information about
Affymetrix, please visit www.affymetrix.com.

Forward-looking statements

All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of the
Securities Exchange Act as amended, including statements regarding Affymetrix'
"expectations," "beliefs," "hopes," "intentions," "strategies," or the like.
Such statements are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the year ended
December 31, 2011, and other SEC reports for subsequent quarterly periods.

Contact:

Affymetrix, Inc.
Media Contact:
Mindy Lee-Olsen, 408-731-5523
Vice President, Marketing Services
mindy_lee-olsen@affymetrix.com
or
Investor Contact:
Doug Farrell, 408-731-5285
Vice President, Investor Relations
doug_farrell@affymetrix.com
or
DNA Link, Inc.
Dr. Jong-Eun Lee, +82-2-3153-1500 (dir +82-2-3153-1501)
CEO
jonglee@dnalink.com